Citation Impact
Citing Papers
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
2009 Standout
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2017 Standout
Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment
2009
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
2008 Standout
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
2005 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial
2017
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
EGFR Antagonists in Cancer Treatment
2008 Standout
Sunitinib in Patients With Metastatic Renal Cell Carcinoma
2006
The FGF family: biology, pathophysiology and therapy
2009 Standout
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
TGF-β signalling-related markers in cancer patients with bone metastasis
2008
Inhibition of RET tyrosine kinase by SU5416
2006
Ranibizumab for Neovascular Age-Related Macular Degeneration
2006 Standout
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
2004 Standout
Angiogenesis and antiangiogenic therapy in hematologic malignancies
2006
New insights into nNOS regulation of vascular homeostasis
2005 StandoutNobel
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways
2005 StandoutNobel
Expression of Vascular Endothelial Growth Factor Receptor 1 in Bone Marrow-derived Mesenchymal Cells Is Dependent on Hypoxia-inducible Factor 1
2006 StandoutNobel
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
2007
Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease
2017
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference
2009 StandoutNobel
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
Biology and management of relapsed acute myeloid leukaemia
2005
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors
2007
Molecular genetics in acute myeloid leukemia
2010
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 Standout
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Point mutations of protein kinases and individualised cancer therapy
2006
Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia
2008
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection
2007
Comprehensive analysis of kinase inhibitor selectivity
2011 Standout
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
2007 StandoutNobel
Astrocyte–endothelial interactions at the blood–brain barrier
2005 Standout
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice
2008 StandoutNobel
The management of brain edema in brain tumors
2004
BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts
2007
The cancer genome
2009 StandoutNature
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease
2018
Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease
2018
Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease Other Than Significant Mitral Stenosis and Mechanical Valves
2017
Acute Myeloid Leukemia
2015 Standout
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
2004 Standout
Tyrosine Kinases as Targets for Cancer Therapy
2005
Transcatheter Mitral-Valve Repair in Patients with Heart Failure
2018 Standout
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2019 Standout
Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations
2006
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
2006
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
2019 Standout
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
2004
Sunitinib: From Rational Design to Clinical Efficacy
2007
Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis
2019
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
2009
Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis
2017
Stromal Cell–Derived Factor-1α and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor
2005 StandoutNobel
Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference
2007 StandoutNobel
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
2005
Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer
2005
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2017 Standout
Hypoxic retinal Müller cells promote vascular permeability by HIF-1–dependent up-regulation of angiopoietin-like 4
2013 StandoutNobel
Comparative Analysis of Mutant Tyrosine Kinase Chemical Rescue
2009 StandoutNobel
Prediction of Resistance to Small Molecule FLT3 Inhibitors
2004
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
2014
LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia
2006 Standout
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
2004
Works of Mark Jacobs being referenced
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease
2016
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
2003
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
2003